NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN) (UM1)

The summary for the NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN) (UM1) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN) (UM1): The purpose of this Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI) is to support an experimental therapeutics clinical trials program through the creation of a consolidated, integrated NCI Experimental Therapeutics-Clinical Trials Network (ET-CTN). This FOA solicits UM1 cooperative agreement applications for multidisciplinary groups that will conduct early phase experimental therapeutics clinical trials. Members of the ET-CTN will work on investigational agent-specific trans-network project teams to define the drug development plan, and to conduct experimental therapeutic clinical trials filed to the Investigational New Drug (IND) applications by NCIs Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).
Federal Grant Title: NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN) (UM1)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-13-006
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.395
CFDA Descriptions: Cancer Treatment Research
Current Application Deadline: Aug 23, 2013
Original Application Deadline: Aug 23, 2013
Posted Date: Feb 08, 2013
Creation Date: Feb 08, 2013
Archive Date: Sep 23, 2013
Total Program Funding: $8,500,000
Maximum Federal Grant Award: $850,000
Minimum Federal Grant Award:
Expected Number of Awards: 10
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply but only if they are based in Canada. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply except for Canadian components. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Grant Announcement Contact
NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants
Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical...
Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial ...
Assay development and screening for discovery of chemical probes, drugs or immunomodulator...
Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed)
The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clini...
Breast and Prostate Cancer Data Quality and Patterns of Care Study
Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults
National Cooperative Drug Discovery Groups for Cancer
More Grants from the National Institutes of Health
Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required)
Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clin...
Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com